Literature DB >> 32712016

Alport Syndrome: Achieving Early Diagnosis and Treatment.

Clifford E Kashtan1.   

Abstract

Alport syndrome is a genetically and phenotypically heterogeneous disorder of glomerular, cochlear, and ocular basement membranes resulting from mutations in the collagen IV genes COL4A3, COL4A4, and COL4A5. Alport syndrome can be transmitted as an X-linked, autosomal recessive, or autosomal dominant disorder. Individuals with Alport syndrome have a significant lifetime risk for kidney failure, as well as sensorineural deafness and ocular abnormalities. The availability of effective intervention for Alport syndrome-related kidney disease makes early diagnosis crucial, but this can be impeded by the genotypic and phenotypic complexity of the disorder. This review presents an approach to enhancing early diagnosis and achieving optimal outcomes.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alport syndrome; COL4A3; COL4A4; COL4A5; basement membranes; collagen IV alpha chain; diagnosis; disease classification; genetic disease; hematuria; kidney failure; proteinuria; review; sensorineural hearing loss; thin basement membrane nephropathy; treatment; type IV collagen

Year:  2020        PMID: 32712016     DOI: 10.1053/j.ajkd.2020.03.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

1.  A diagnostic confidence scheme for CLN3 disease.

Authors:  Margaux C Masten; Camille Corre; Alex R Paciorkowski; Amy Vierhile; Heather R Adams; Jennifer Vermilion; Grace A Zimmerman; Erika F Augustine; Jonathan W Mink
Journal:  J Inherit Metab Dis       Date:  2021-09-07       Impact factor: 4.750

Review 2.  A Practical Guide to Genetic Testing for Kidney Disorders of Unknown Etiology.

Authors:  Abraham W Aron; Neera K Dahl; Whitney Besse
Journal:  Kidney360       Date:  2022-07-08

3.  A pedigree with COL4A5 mutation presenting with Alport syndrome and focal segmental glomerulosclerosis lesions: a case report.

Authors:  Honghong Zou; Li Zhu; Rong Xu; Sufang Shi; Suxia Wang; Fude Zhou; Hong Zhang; Minghui Zhao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

4.  The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation.

Authors:  Eva Schrezenmeier; Elisa Kremerskothen; Fabian Halleck; Oliver Staeck; Lutz Liefeldt; Mira Choi; Markus Schüler; Ulrike Weber; Nadine Bachmann; Maik Grohmann; Timo Wagner; Klemens Budde; Carsten Bergmann
Journal:  Genet Med       Date:  2021-03-12       Impact factor: 8.822

Review 5.  Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease.

Authors:  Xiaoli Sun; Youhua Liu
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

6.  A disease-causing variant of COL4A5 in a Chinese family with Alport syndrome: a case series.

Authors:  Jing Wu; Jun Zhang; Li Liu; Bo Zhang; Tomohiko Yamamura; Kandai Nozu; Masafumi Matsuo; Jinghong Zhao
Journal:  BMC Nephrol       Date:  2021-11-13       Impact factor: 2.388

Review 7.  The Contribution of COL4A5 Splicing Variants to the Pathogenesis of X-Linked Alport Syndrome.

Authors:  Tomohiko Yamamura; Tomoko Horinouchi; Yuya Aoto; Rachel Lennon; Kandai Nozu
Journal:  Front Med (Lausanne)       Date:  2022-02-08

Review 8.  Current Advances in RNA Therapeutics for Human Diseases.

Authors:  Hannah Zogg; Rajan Singh; Seungil Ro
Journal:  Int J Mol Sci       Date:  2022-03-01       Impact factor: 5.923

9.  Case Report: Identification of a Novel Heterozygous Missense Mutation in COL4A3 Gene Causing Variable Phenotypes in an Autosomal-Dominant Alport Syndrome Family.

Authors:  Yanglin Hu; Wei Li; Lulu Tian; Shuai Fu; Yonglong Min; Jia Liu; Fei Xiong
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

10.  Alport syndrome combined with lupus nephritis in a Chinese family: A case report.

Authors:  Hui-Fang Liu; Qing Li; You-Qun Peng
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.